Microchips Biotech has developed an implantable technology that releases drugs in the body in a controlled manner.
Though the technology was developed a decade ago, it is only now that it is introduced for use.
The company has now partnered with Teva Pharmaceutical to
produce the initial product and put it through clinical trials.
The implantable chip has tiny reservoirs, each containing one dose of a
particular medication. A metal membrane caps top of these reservoirs, which can
be moved out of the way by delivering an electric current.
Depending on the applied current each reservoir can be individually
activated to open up, allowing for administration at the exact times and even with multiple medications.
The company's microchips have already gone through a successful clinical trial on patients with osteoporosis, delivering teriparatide
directly without having to go through regular injections.
The study demonstrated that the programmable implant was able to deliver the
drug at scheduled intervals. Drug delivery and evaluation in patients occurred
over a one month period and provided proof-of-concept measures of drug release
and device durability that support implantable device viability for 12 months
"A microchip that continues to deliver teriparatide
with this or similar consistency and efficiency over 12 to 24 months could
improve bone mass, density, architecture, and strength," said study co-author
Robert Neer, Founder & Director of the Massachusetts General Hospital Bone
Density Center and Associate Professor of Medicine at Harvard Medical School.